CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 11 No. 3
The Meyn Article Reviewed 

Apoptosis and Response to Radiation: Implications for Radiation Therapy

By

Eric J. Hall, DPHIL, DSc, FACR, and Eileen Rakovitch, MD, FRCPC
College of Physicians & Surgeons Columbia University, New York | March 1, 1997


Quantitative radiation biology was revolutionized in 1956 when Puck and Marcus published the first cell survival curve, relating radiation dose to the fraction of cells surviving.[1] The term "survival" generated a great deal of discussion at that time and led to the definition of such terms as "reproductive death," "reproductive integrity," and "clonogenicity" (among others), all designed to explain that the end point of cell culture experiments is the loss of the cell's ability to divide indefinitely and produce a sizable visible clone.

This technique does not distinguish between modes or times of cell death, however. The end point is bottom line-oriented! It also should be noted that the Puck and Marcus paper involved HeLa cells, for which apoptosis is an important form of cell death. It is true that soon thereafter, various hamster cell lines were developed (with which many of the principles of radiobiology were demonstrated), which do not undergo apoptosis at all, but the earliest work was with HeLa cells, which do.

Meanwhile, the development of autoradiography had made possible the study of cell and tissue kinetics, leading to the concepts of growth fraction and cell loss factor in tumor biology. From a study of a multitude of animal tumors, Denekamp proposed that, in general, carcinomas respond rapidly to radiation because they have a large cell loss factor, while sarcomas respond slowly because they have a small cell loss factor.[2] (Response, of course, does not necessarily relate to a final "cure.")

It is within this historical framework that the study of apoptosis has progressed, with many of the Old Guard being slow to be convinced that it is important in radiation therapy. The review article by Dr. Meyn is informative and timely, for he has worked in this area for many years and is respected for his thoughtful judgment.

The Central Unaddressed Question

Dr. Meyn distinguishes between apoptosis and reproductive cell death. We disagree somewhat with this point. By all means, distinguish between apoptosis and mitotic death. The latter is defined as death in attempting mitosis due to illegitimate chromosomal rejoining. But both apoptosis and mitotic death are forms of reproductive cell death; no distinction is made between them in the conventional colony-forming assay. Nor is a distinction made between primary and secondary apoptosis.

Dr. Meyn does a singular service in pointing out that the distinction between primary and secondary apoptosis is not trivial. If apoptosis is simply a means of removing the debris after the cell is already dead from chromosomal abnormalities, it is not of much interest. To the extent that apoptosis represents a different, radiosensitive mode of cell death, however, it is of vital interest. This leads to the central, but unaddressed question: Why do cells from the same individual, which harbor shared genetic material, die a rapid apoptotic death if they arise in the hematopoietic system and a mitotic death if they are of epithelial or fibroblastic origin?

Clearly, further work is required to investigate the molecular basis of the apoptotic response, particularly following exposure to ionizing radiation. The tumor-suppressor gene p53 is one gene known to mediate apoptosis; however, its effect on cellular radiosensitivity remains controversial. Slichenmyer et al have shown no effect on radiosensitivity when a dominant-negative mutant of p53 was transfected into a human colorectal carcinoma cell line.[3] Lee and Bernstein demonstrated increased resistance to radiation in hematopoietic cells derived from transgenic mice expressing mutant alleles of p53; however, this effect was not due to loss of programmed cell death.[4]

For the apoptotic index to serve as a useful biologic marker, it must be able to identify the subset of patients with radiocurable disease. Further studies are required to investigate the association between spontaneous apoptosis and radiation-induced apoptosis, as well as the independent prognostic significance of the spontaneous apoptotic index. If spontaneous apoptosis and radiation-induced apoptosis are unrelated, the presence of spontaneous apoptosis could lead to misclassification in assays assessing radiation-induced apoptosis, subsequently reducing the likelihood that the assay would have any predictive power.

Study of Apoptosis Still Evolving

It seems to us that in the study of apoptosis, we are long on data and short on understanding. Put more kindly, perhaps, the study of apoptosis is in a descriptive phase, with many correlations being found, but with no discovery that is of much real consequence. We have replaced "sensitive vs resistant cells" with "cells that die an apoptotic death vs those that do not," and "tumors that respond rapidly to radiation" with "tumors showing a propensity toward radiation-induced apoptotic death." The terminology and nomenclature have changed, but the outcome is not much altered.

As in so many areas of cancer research in general, and radiation biology in particular, recent discoveries at the molecular level give a tantalizing glimpse of the mechanisms underlying the phenomena that we have known about for so long. But we have not gone beyond that yet. Manipulating the biology to achieve a therapeutic gain remains an elusive possibility reserved for some future date.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.



Raymond E. Meyn, PhD


1. Puck TT, Markus PI: Action of x-rays onmammalian cells. J Exp Med 103:653-666, 1956.

2. Denekamp J: The relationship between the "cell loss factor" and the immediate response to radiation in animal tumours. Eur J Cancer 8:335, 1972.

3. Lee JM, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci 90:5742-5746, 1993.

4. Slichenmyer WJ, Nelson WG, Slebos RJ, et al: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53:4164-4168, 1993.


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

A 48-Year-Old Woman With Irregular Vaginal Bleeding
Brian Morse, MD1 , June 10, 2013

A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy